The emerging field of Pharmacometabolomics aims at the assessment of phenotypic changes related to disease and/or drug response via the analysis of small molecules and lipids in biological samples. By employing quantitative, targeted and non-targeted metabolomic profiling methods our group focuses on the comprehensive examination of metabolic factors contributing to cancer and metabolic disease, thereby supporting the evaluation of novel diagnosis and treatment options for personalized therapy. Metabolomics measurements are further applied for the investigation of metabolic cross talk within cellular microenvironments and a potential contribution of non-genetic factors (e.g. microbiome) to chemosensitivity, drug metabolism and drug response variability.